$LEXX 🚨 KEEP THIS ON YOUR RADAR 🚨💰

Key upcoming catalysts: - MTA with big pharma Q1/Q2 - Multiple on-going negotiations with big pharma as per PR - Fully funded in 2026 - Only company in existence to prove 40-60% reduction in AEs across all three major GLP1 peptides with superior brain absorption Since mid-2025, the Lexaria story has quietly evolved in a way that’s easy to miss if you’re only watching the share price. Over that period, the company moved from early clinical promise to something far more concrete. Multiple human GLP-1 studies were completed, culminating in a Phase 1b trial that showed DehydraTECH-delivered semaglutide produced materially fewer GI side effects than Rybelsus while maintaining metabolic effectiveness over chronic dosing. Follow-up data added important nuance, including better patient-reported quality-of-life scores, intriguing fat-to-lean mass preservation, and unexpected blood pressure reductions that hint at broader cardiovascular and hypertension applications. What’s notable is how the science, capital strategy, and IP expansion have all progressed in parallel. Since mid-2025, Lexaria raised capital at relatively strong prices, extending its runway through all of 2026, while continuing to execute on research rather than retrenching. At the same time, the company has aggressively fortified its intellectual property, now reaching 60 granted patents worldwide. Recent additions in Europe and Australia cover hypertension, diabetes, epilepsy, and nicotine delivery — high-value markets that companies only protect when commercial relevance is credible. The timing of diabetes and cardiovascular IP expansion right after positive GLP-1 data feels deliberate, especially with a partner reviewing the full dataset under an extended MTA. This is why a potential follow-on study combining SNAC with DehydraTECH has become such a focal point. SNAC is closely tied to existing oral GLP-1 IP, and its inclusion would strongly suggest deeper partner involvement rather than passive evaluation. With funding secured, data de-risked, and IP locked down, the narrative has shifted. This no longer feels like an early-stage science experiment, but a delivery platform entering serious partner-level scrutiny — and that’s where things typically start to get interesting.